Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07468630 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma

Study acronym: TRIUNITE-08
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This multicenter, randomized, open-label, blinded-endpoint Phase II trial assesses the efficacy and safety of tolecizumab (PCSK9 inhibitor) plus sintilimab/CapeOX chemoimmunotherapy as neoadjuvant treatment for pMMR/MSS locally advanced colon adenocarcinoma (cT3c+). 106 patients are 1:1 randomized to the combination or chemoimmunotherapy alone, with pCR as the primary endpoint.
Trial Details
NCT Number NCT07468630
Lead Sponsor Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Collaborators: Southwest Hospital, China, Chongqing Shapingba District People's Hospital
Conditions
(from sponsor)		 Colon Adenocarcinoma
Related terms Colonic Neoplasms
Enrollment 106 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov